178 related articles for article (PubMed ID: 3258627)
1. Suppression of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity in mouse brain by piroheptine and trihexyphenidyl.
Saitoh T
J Neurol Sci; 1988 Feb; 83(2-3):161-6. PubMed ID: 3258627
[TBL] [Abstract][Full Text] [Related]
2. N-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine increases acetylcholine and decreases dopamine in mouse striatum: both responses are blocked by anticholinergic drugs.
Hadjiconstantinou M; Cavalla D; Anthoupoulou E; Laird HE; Neff NH
J Neurochem; 1985 Dec; 45(6):1957-9. PubMed ID: 3877147
[TBL] [Abstract][Full Text] [Related]
3. Dopamine uptake blockers protect against the dopamine depleting effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse striatum.
Ricaurte GA; Langston JW; DeLanney LE; Irwin I; Brooks JD
Neurosci Lett; 1985 Sep; 59(3):259-64. PubMed ID: 3932903
[TBL] [Abstract][Full Text] [Related]
4. Exposure to cigarette smoke does not decrease the neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
Perry TL; Hansen S; Jones K
Neurosci Lett; 1987 Feb; 74(2):217-20. PubMed ID: 3494963
[TBL] [Abstract][Full Text] [Related]
5. Amine fluorescence histochemical investigation of the striatum in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP)-induced parkinsonian mice.
Mizukawa K; Ogawa N; Sora YH
Res Commun Chem Pathol Pharmacol; 1988 Jan; 59(1):121-8. PubMed ID: 3258432
[TBL] [Abstract][Full Text] [Related]
6. Dopamine but not norepinephrine or serotonin uptake inhibitors protect mice against neurotoxicity of MPTP.
Melamed E; Rosenthal J; Cohen O; Globus M; Uzzan A
Eur J Pharmacol; 1985 Oct; 116(1-2):179-81. PubMed ID: 3876943
[TBL] [Abstract][Full Text] [Related]
7. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors.
Heikkila RE; Manzino L; Cabbat FS; Duvoisin RC
Nature; 1984 Oct 4-10; 311(5985):467-9. PubMed ID: 6332989
[TBL] [Abstract][Full Text] [Related]
8. Chronic L-deprenyl does not alter the restoration of striatal dopamine in MPTP-lesioned mice.
Wiener HL; Hashim A; Lajtha A; Sershen H
J Neurosci Res; 1989 Jul; 23(3):326-9. PubMed ID: 2504936
[TBL] [Abstract][Full Text] [Related]
9. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) in the mouse: relationships between monoamine oxidase, MPTP metabolism and neurotoxicity.
Heikkila RE; Hess A; Duvoisin RC
Life Sci; 1985 Jan; 36(3):231-6. PubMed ID: 3917525
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the neurotoxic potential of m-methoxy-MPTP and the use of its N-ethyl analogue as a means of avoiding exposure to a possible Parkinsonism-causing agent.
Zimmerman DM; Cantrell BE; Reel JK; Hemrick-Luecke SK; Fuller RW
J Med Chem; 1986 Aug; 29(8):1517-20. PubMed ID: 3488406
[TBL] [Abstract][Full Text] [Related]
11. GM1 ganglioside-induced recovery of nigrostriatal dopaminergic neurons after MPTP: an immunohistochemical study.
Hadjiconstantinou M; Mariani AP; Neff NH
Brain Res; 1989 Apr; 484(1-2):297-303. PubMed ID: 2565752
[TBL] [Abstract][Full Text] [Related]
12. Influence of selective, reversible inhibitors of monoamine oxidase on the prolonged depletion of striatal dopamine by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
Fuller RW; Hemrick-Luecke SK
Life Sci; 1985 Sep; 37(12):1089-96. PubMed ID: 3875779
[TBL] [Abstract][Full Text] [Related]
13. MK-801 temporarily prevents MPTP-induced acute dopamine depletion and MPP+ elimination in the mouse striatum.
Chan P; Langston JW; Di Monte DA
J Pharmacol Exp Ther; 1993 Dec; 267(3):1515-20. PubMed ID: 8263813
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity to striatal dopamine neurons in mice.
Fuller RW; Hemrick-Luecke SK
Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(5-6):687-90. PubMed ID: 3878976
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effects of two 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs, 1-methyl-4-(2-thienyl)-1,2,3,6-tetrahydropyridine and 1-methyl-4-(3-thienyl)-1,2,3,6-tetrahydropyridine, on monoamine oxidase in vitro and on dopamine in mouse brain.
Fuller RW; Robertson DW; Hemrick-Luecke SK
J Pharmacol Exp Ther; 1987 Feb; 240(2):415-20. PubMed ID: 3100775
[TBL] [Abstract][Full Text] [Related]
16. Effect of amphetamine on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in mice.
Sershen H; Mason MF; Reith ME; Hashim A; Lajtha A
Neuropharmacology; 1986 Aug; 25(8):927-30. PubMed ID: 3490630
[TBL] [Abstract][Full Text] [Related]
17. The use of the MPTP-treated mouse as an animal model of parkinsonism.
Heikkila RE; Sonsalla PK
Can J Neurol Sci; 1987 Aug; 14(3 Suppl):436-40. PubMed ID: 3499967
[TBL] [Abstract][Full Text] [Related]
18. Characterization of hepatic microsomal metabolism as an in vivo detoxication pathway of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
Chiba K; Kubota E; Miyakawa T; Kato Y; Ishizaki T
J Pharmacol Exp Ther; 1988 Sep; 246(3):1108-15. PubMed ID: 3262153
[TBL] [Abstract][Full Text] [Related]
19. [Study of extracellular concentration of dopamine and its metabolites in mice striatum by a microdialysis technique at intraperitoneal administration of MPTP].
Averkin RG; Korshunov VA; Shchegolevskiĭ NV; Mats VN; Markevich VA; Grigor'ian GA; Bazian AS
Zh Vyssh Nerv Deiat Im I P Pavlova; 2010; 60(1):109-19. PubMed ID: 20352690
[TBL] [Abstract][Full Text] [Related]
20. A high dose of MPTP overcomes the protective effect of selegiline against dopaminergic neurotoxicity.
Fuller RW; Hemrick-Luecke SK
J Pharm Pharmacol; 1989 Jul; 41(7):492-3. PubMed ID: 2570859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
